ArticleBMC cancer2025
Prognostic and diagnostic value of PVR gene and protein levels, serum amylase, and urinary IGFBP-7 and TIMP-2 biomarkers in multiple myeloma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple Myeloma (MM) is a plasma cell malignancy associated with systemic and renal complications. This study evaluates the prognostic and diagnostic significance of poliovirus receptor (PVR) gene expression and protein levels, serum amylase, and urinary biomarkers (IGFBP-7, TIMP-2) in MM patients.
methodsIn a prospective case-control study, 50 MM patients and 50 healthy controls were assessed. PVR gene expression (qPCR), serum PVR and amylase (ELISA/chemistry analyzer), and urinary IGFBP-7 and TIMP-2 (ELISA) were analyzed. Statistical analyses included correlation tests, Kaplan-Meier survival analysis, Cox regression, stratified quartile analysis, and receiver operating characteristic (ROC) curve evaluation. Multiple testing corrections (Bonferroni and FDR) were applied.
resultsMM patients showed significantly elevated PVR expression and protein levels, serum amylase, and urinary biomarkers compared to controls (p<0.001). High PVR expression was associated with advanced disease stage, TP53 mutations, and reduced overall survival (OS: 44.84 vs. 48.0 months; p=0.044). High serum amylase and urinary IGFBP-7 were linked to significantly poorer OS and progression-free survival (PFS). Multivariate Cox regression confirmed PVR expression (HR=12.2), serum amylase (HR=11.5), and IGFBP-7 (HR=11.9) as independent predictors of poor OS, findings that remained robust in bootstrapped and penalized regression models. Stratified analysis revealed that patients in the highest biomarker quartiles had significantly worse outcomes and higher TP53 mutation rates. ROC analysis showed excellent diagnostic performance for the combined panel (PVR + amylase + IGFBP-7; AUC=0.97, sensitivity =90%, specificity = 88%), outperforming individual markers. Significant associations remained after multiple testing correction.
conclusionPVR gene expression, serum amylase, and urinary IGFBP-7 are independent and robust prognostic biomarkers in MM. Their combined use enhances diagnostic accuracy and risk stratification, supporting their integration into clinical decision-making. Validation in larger, multi-center studies is recommended. Limitations include the single-center design, modest sample size, absence of disease comparator groups, and the cross-sectional nature of biomarker evaluation. These findings warrant validation in larger, multi-institutional, and longitudinal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.